成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Cancer treatment reviews >>article
Cancer treatment reviews

Cancer treatment reviews

IF: 9.59
Download PDF

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Published:1 November 2020 DOI: 10.1016/j.ctrv.2020.102105 PMID: 32979839
Jordi Remon , Lizza E.L. Hendriks , Andres F. Cardona , Benjamin Besse

Abstract

Although targeted therapy is standard of care in a large subset of oncogenic addicted non-small cell lung cancers (NSCLC), until recently, this therapeutic approach has not been feasible for all genomic alterations such as for those tumors harboring Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations. Despite being the third most common EGFR mutation, a limited efficacy of first- and second-generation EGFR tyrosine kinase inhibitors (TKI) exists. This is related to the heterogeneity at the molecular level in EGFR ex20ins mutation variants and the finding that this mutation promotes active kinase conformation but does not increase the affinity for EGFR TKI. As a result, the prognosis of this population is diminished. Therefore, chemotherapy remained the most suitable strategy in this subset of EGFR mutant NSCLC patients. Recently, new treatment strategies have been reported in this landscape, either with new EGFR TKI or bispecific antibodies, which may establish a new standard of care in the coming future for these patients. Future research should focus on elucidating the oncogenic degree of all EGFR ex20ins variants, the potential role of combination strategies either with chemotherapy or immune checkpoint inhibitors, and the most appropriate first-line treatment strategy in this subgroup. Finally, the knowledge of mechanisms of acquired resistance to these new agents upon progression is a priority for personalising treatment at that time. It is in this framework, that we provide a thorough overview on this subject.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Kinase inhibitor-1 2135696-72-7 C19H18BrClN6O 17 suppliers Inquiry
EGFR-HER2 Ex20Ins inhibitor 1a 2068806-31-3 C25H22FN7O3 15 suppliers Inquiry
EGFR 7 suppliers Inquiry

Similar articles

IF:3

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

Saudi Pharmaceutical Journal Silky Bedi , Shah A. Khan ,etc Published: 1 September 2018
IF:12.7

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.

ACS Central Science Sabrina Baltschukat, Barbara Schacher Engstler,etc Published: 15 May 2019